Perspectives

How does this study impact clinical practice?

• Based on these pooled data, ligelizumab demonstrated an efficacy profile superior to placebo, but not to omalizumab.
• The safety profile was consistent with previous studies, with no new signals.
• Ligelizumab is effective in CSU, and may represent a new treatment option for patients.